Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.72 -0.18 (-1.82%) Market Cap: 17.43 Bil Enterprise Value: 21.25 Bil PE Ratio: 4,243.06 PB Ratio: 1.82 GF Score: 77/100

Q1 2022 Astellas Pharma Inc Earnings Call Transcript

Jul 30, 2021 / 07:00AM GMT
Release Date Price: $15.92 (-8.31%)
Naoki Okamura
Astellas Pharma Inc. - Executive VP, CFO, Chief Strategy Officer & Representative Director

Hello, everyone. I'm CSO and CFO at Astellas Pharma Inc. I'm Naoki Okamura. Thank you very much for joining our conference call on our financial results for the first quarter of fiscal year 2021.

As usual, I will give you an overview of financial results and explain our initiatives for sustainable growth. It maybe unusual to say what is not in the script at the beginning. But first of all, we'd like to apologize for the first quarter results, which are not as good as we expected.

So looking at the (inaudible) of the stock market, it reflects the feelings of the investors. So we apologize to the shareholders as well. We are announcing our CSP plan, but we are not complacent. Maybe we were not so careful about what we are doing right now. And so we try to deliver the fiscal year 2021 results. So we'd like to do our best.

Let me move on. Page 2 is a cautionary statement regarding forward-looking information read by (inaudible). So I'd like to skip.

Page 3. Today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot